Summary
The product Retatrutide red top vial, submitted by Alchemist Peptides, underwent independent testing to verify its composition and purity. The sample, identified by Task Number #45420, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis confirmed the presence of Retatrutide at a concentration of 10.75 mg with a purity of 99.681%.
The testing process began on 4 July 2024, with the sample received on 15 July 2024, and analysis completed on 17 July 2024. While the results confirm a high purity level, careful consideration of manufacturer-submitted samples is essential. manufacturer may select specific batches that meet quality standards, raising questions about consistency across the broader market. Independent third-party testing remains crucial to validating these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Alchemist Peptides
- Product Name: Retatrutide red top vial
- Active Ingredient: Retatrutide
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Raw Powder
Testing Details
- Task Number: #45420
- Testing Ordered: 4 July 2024
- Sample Received: 15 July 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Alchemist Peptides (Manufacturer)
- Analysis Paid For By: Alchemist Peptides (Manufacturer)
Testing Results
- Specification: Not provided
- Measured Concentration: 10.75 mg
- Purity: 99.681%
Verification Details
- Verification URL: https://janoshik.com/tests/45420_U789CJHHLN83
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by the manufacturer Alchemist Peptides. manufacturers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Retatrutide red top vial contains 10.75 mg of Retatrutide with an exceptionally high purity of 99.681%. While this suggests a high-quality batch, additional testing is recommended to ensure consistent dosing across all products. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
